A case of pulmonary toxicity associated with G-CSF and doxorubicin administration.
The cytokine growth factor, G-CSF (granulocyte colony-stimulating factor), is commonly used in oncologic practice and is generally believed to be a safe agent to administer. We describe here a case of pulmonary toxicity associated with the concurrent administration of G-CSF and doxorubicin. We contend that G-CSF contributed to the life-threatening lung injury in our patient, and discuss additional reports in the literature of pulmonary toxicity associated with the use of this agent.
Eisenbeis
C F
CF
Department of Medicine, University of Chicago Medical Center, Chicago, Ill., USA.
Winn
D
D
Poelman
S
S
Polsky
C V
CV
Rubenstein
J H
JH
Olopade
O I
OI
D001706:Biopsy; D001980:Bronchi / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000633:toxicity*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000633:toxicity*; D006801:Humans; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced*
D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin